Vir Biotechnology reveals two-year data for experimental hepatitis delta therapy

Vir Biotechnology will release complete 96-week data from the SOLSTICE trial in May 2026, evaluating tobevibart (VIR-3434) alone or combined with elebsiran (VIR-2218) for chronic hepatitis delta, an orphan disease with no FDA-approved treatments. Tobevibart is a broadly neutralizing monoclonal antibody targeting hepatitis B surface antigen, while elebsiran, an siRNA licensed from Alnylam, reduces HBsAg; both are administered monthly as two sequential subcutaneous injections. The oral presentation at the European Association for the Study of the Liver Congress on May 29 was selected for inclusion in "Best of EASL 2026," signaling the rigor and clinical weight of the findings. A complementary subgroup analysis will examine how body mass index influences ALT normalization after viral control—data with real implications for predicting treatment response across heterogeneous patient populations. For the hepatitis delta patient and the longevity-focused clinician seeking novel therapeutic options, two years of controlled trial data represent a watershed moment in treating a historically untreatable disease.